Rising Prevalence Of Skin Infections Fuels Growth In The Macrolide Antibiotics Market: The Driving Engine Behind Macrolide Antibiotics Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Macrolide Antibiotics Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a quick expansion in the market size of macrolide antibiotics. It is projected to surge from $59.07 billion in 2024 to $66.02 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 11.8%. The notable growth during the historic period is a result of rising antibiotic resistance, approval of novel formulations, increase in prevalence of infectious diseases, and initiatives taken by governments and healthcare institutions.

How Will the Macrolide Antibiotics Market Size Evolve and Grow by 2029?
In the coming years, the market size of macrolide antibiotics is anticipated to expand rapidly, reaching $102.09 billion in 2029, with a compound annual growth rate (CAGR) of 11.5%. The projected growth in this period can be credited to the escalation in respiratory infections, increase in combination therapies, a surge in the global elderly population, improved awareness and diagnostics, and the growth of telemedicine and online pharmacy services. Key trends for the forecast period encompass improvements in drug delivery systems and formulations, the invention of new macrolide antibiotics, advances in remote healthcare and telemedicine services, and the establishment of environmentally-friendly production processes for macrolide antibiotics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

What Drivers Are Propelling the Growth of Macrolide Antibiotics Market Forward?
Rising cases of skin infections are anticipated to fuel the expansion of the macrolide antibiotics market. Skin infections emerge due to detrimental microorganisms penetrating the skin, initiating inflammation, and often exhibiting symptoms such as redness, swelling, and discomfort. Factors contributing to the escalation of skin infections include unhygienic practices, weakened immune systems, contamination from environmental pollutants, antibiotic resistance, and inadequate wound care. Macrolide antibiotics are typically recommended for the treatment of bacterial skin infections, particularly ones caused by Staphylococcus aureus or Streptococcus pyogenes, especially when there is an allergy or resistance to penicillin. As an example, the UK Health Security Agency (UKHSA), a national executive agency based in the UK, reported in September 2022 that the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases due to skin and soft tissue infections increased from 25.7% in the fiscal year from April 2020 to March 2021, to 33.7% in the next fiscal year from April 2021 to March 2022. Likewise, for Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia cases, the percentage rose from 27.2% to 28.5% within the same timeframe. Thus, the escalating frequency of skin infections is contributing to the growth of the macrolide antibiotics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16472&type=smp

Which Emerging Trends Are Transforming the Macrolide Antibiotics Market in 2025?
Leading businesses in the macrolide antibiotic market are concentrating on producing generic versions of their medications in order to enhance access, decrease the cost of treatment, and widen their market presence. Generic versions of macrolide antibiotics are unbranded renditions of these medicines that maintain the same active ingredients, dosage, and potency as the original, branded drugs. For instance, Phantom Pharmaceuticals, a company based in the United States, introduced two products in May 2022, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, both geared towards treating Helicobacter pylori (H. pylori) infection in adults. VOQUEZNA TRIPLE PAK includes vonoprazan, an acid blocker that competes with potassium, alongside amoxicillin and clarithromycin, while VOQUEZNA DUAL PAK is composed of vonoprazan and amoxicillin. This represents a breakthrough because it is the first time a new class of acid suppressants has been approved in the U.S. in over three decades.

What Are the Key Segments in the Macrolide Antibiotics Market?
The macrolide antibiotics market covered in this report is segmented -

1) By Drugs: Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin
2) By Indication: Respiratory Tract Infections, Skin Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
5) By End User: Hospital, Dermatology Clinic, Clinic, Ambulatory Centre, Research Laboratories

Subsegments:
1) By Azithromycin: Oral Tablets, Oral Suspension, Injection
2) By Clarithromycin: Immediate-Release Tablets, Extended-Release Tablets, Oral Suspension
3) By Erythromycin: Tablets, Capsules, Topical Solution, Injection
4) By Fidaxomicin: Oral Tablets
5) By Telithromycin: Oral Tablets

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16472&type=smp

Who Are the Key Players Shaping the Macrolide Antibiotics Market's Competitive Landscape?
Major companies operating in the macrolide antibiotics market are Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyo, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited

What Geographic Markets Are Powering Growth in the Macrolide Antibiotics Market?
North America was the largest region in the macrolide antibiotics market in 2024. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16472

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.